HRASLS3 Antibody

Product Specifications

Background

PLA2G16 specifically catalyzes the release of fatty acids from phospholipids in adipose tissue. It also has a weak lysophospholipase activity (By similarity) . Tumor suppressor that may be involved in interferon-dependent cell death.

NCBI Gene ID

11145

Swiss Prot

P53816

Accession Number

P53816

Host

Rabbit

Reactivity

Human, Mouse

Immunogen

This HRASLS3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 104-132 amino acids from the C-terminal region of human HRASLS3.

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Cancer

Purification

This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis

Concentration

Batch dependent

Buffer

Supplied in PBS with 0.09% (W/V) sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Store at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Calculated Molecular Weight

18 kDa

Fragment

Rabbit Ig

Symbol

PLA2G16

NCBI Official Name

HRAS-like suppressor 3

NCBI Organism

Homo sapiens

Background Reference 01

Uyama, T., et al. Biochim. Biophys. Acta 1791 (12) :1114-1124 (2009)

Background Reference 02

Duncan, R.E., et al. J. Biol. Chem. 283 (37) :25428-25436 (2008)

Background Reference 03

Nazarenko, I., et al. J. Cell. Sci. 120 (PT 8), 1393-1404 (2007)

Background Reference 04

Nazarenko, I., et al. Am. J. Pathol. 169 (4) :1427-1439 (2006)

Other Product Names

HRAS-like suppressor 3, HRSL3, Adipose-specific phospholipase A2, AdPLA, Group XVI phospholipase A1/A2, H-rev 107 protein homolog, HRAS-like suppressor 1, HREV107-1, HREV107-3, Renal carcinoma antigen NY-REN-65, PLA2G16, HRASLS3, HREV107